Found 469 results in Expert Content

Learn how to accelerate and de-risk clinical-stage drug programs by understanding phase-appropriate strategies that can give your molecule the best chance for success!

Listen to this webinar to hear experts share insights into developing intranasal vaccine analytical tools, how to improve the speed and quality of critical batch release and characterization assays and the importance of device selection in determining product performance.

An advanced development offering that integrates formulation expertise with on-demand Phase 1 clinical manufacturing, adaptive clinical testing and regulatory support, to help achieve flexible and efficient First-in-Human studies and expedited development.

The aim of this study was to verify if the GastroPlus® PBPK software can be used to predict intranasal absorption by comparing predictions with human intranasal pharmacokinetic data from the literature.

Watch this webinar to gain insights into current market trends in dry powders for inhalation, the key capsule characteristics that determine performance and the fundamental physical characteristics of spray-dried and lactose-based powders that contribute to the efficiency of the encapsulation process.

Summary: In this executive summary, learn how to gather the right team to translate benchtop discoveries into clinical trials, and more.

Summary: In this Q&A article, experts discuss intranasal drug product development, in particular best practices and key considerations, from formulation design to manufacture and scale-up.

Summary: In this executive summary, we describe the benefits of controlled release, how to determine whether a drug is suitable for controlled release and more.

Hear from a panel of experts on the critical challenges of spray dried powder formulation development, risk mitigation strategies and more.

Summary: In this webinar, experts will explore the journey from molecule candidate selection to first-in-human clinical studies, discussing the process from initial formulation conception to forming accelerated pathways to clinical trials.